GlassScriptPhysician profile
Muhammad T Selevany
NPI 1588758809
$12,796.85
in general payments reported to CMS, 2019-2025
49 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $1,390 · 2021: $2,190 · 2022: $2,337 · 2023: $2,197 · 2024: $1,867 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,935 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,935.35 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,474.61 | 2019-2025 | Qulipta, Ubrelvy, Linzess |
| Gilead Sciences, INC. | $1,483.00 | 2019-2025 | Biktarvy, Veklury |
| Amgen INC. | $1,254.01 | 2019-2025 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $779.48 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Glaxosmithkline, LLC. | $636.05 | 2019-2025 | Trelegy Ellipta |
| Viiv Healthcare Company | $547.89 | 2020-2025 | Dovato |
| Novo Nordisk INC | $511.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $464.61 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Pfizer INC. | $425.34 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.59 | 2019-2025 | Jardiance |
| Emd Serono, INC. | $291.38 | 2024-2025 | |
| Lilly USA, LLC | $289.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $276.25 | 2021-2023 | |
| Redhill Biopharma INC. | $272.30 | 2020-2022 | |
| Amarin Pharma, INC. | $257.16 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Selevany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.